[In vitro studies of the effect of different mixture proportions of omega-3 and omega-6 fatty acids on thrombocyte aggregation and thromboxane synthesis in human thrombocytes].
In order to estimate the influence of the tested fatty acids on platelet aggregation, synthesis of prostaglandin E and thromboxane B in vitro, platelet rich plasma (PRP) was incubated with the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with linoleic acid as representative of the omega-6 fatty acids, as well as with mixtures of EPA and DHA and all fatty acids, resp., with and without addition of alpha-tocopherol. For the determinations, platelets were prepared from blood of young adult male volunteers (age 26.6 +/- 8 years). Platelet aggregation and synthesis of thromboxane were measured after 30 and 60 min of incubation. Smoking habits were not regarded. The incubation of platelets with DHA and EPA itself, as well as the mixture of fatty acids dominated by omega-3 fatty acids (omega-3/omega-6 = 15/1) caused a significant decrease (p less than 0.05) of collagen-induced platelet aggregation. Tocopherol, linoleic acid, and the linoleic-acid-rich mixtures (omega-3/omega-6 = 1/4) caused only a slight inhibition of platelet aggregation. No uniform influence of omega-3 fatty acids could be observed that showed their influence on synthesis of thromboxane to be of importance for the promotion of platelet aggregation. EPA and the mixture of EPA and DHA did decrease thromboxane synthesis significantly (p less than 0.05). On the other hand, single incubation with DHA as well as with linoleic acid rich mixtures caused a statistically not significant increase of rate of the synthesis, which did not increase the aggregation. This observation indicates the formation of less effective TXA3. An influence of tocopherol could also not be observed.
Stroh
S
S
Institut für Ernährungswissenschaft, Universität Wien.
Elmadfa
I
I
D000328:Adult; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D006801:Humans; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000494:pharmacology*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011458:Prostaglandins E / Q000096:biosynthesis; D013931:Thromboxanes / Q000096:biosynthesis*; D014810:Vitamin E / Q000494:pharmacology
D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D010975:Platelet Aggregation Inhibitors; D011458:Prostaglandins E; D013931:Thromboxanes; D014810:Vitamin E; D019787:Linoleic Acid; D015118:Eicosapentaenoic Acid; C026219:docosapentaenoic acid
In-vitro-Untersuchungen zum Einfluss verschiedener Mischungsverhältnisse an omega-3- und omega-6-Fettsäuren auf die Thrombozytenaggregation und Thromboxansynthese in Humanthrombozyten.